Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product License for SmoothX; Radiographic Barium Contrast Suspension
Calgary, Alberta – February 12, 2021 – Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) USA (OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for SmoothX. SmoothX is a barium radiographic contrast suspension that is specifically formulated for computed tomography procedures (CT Scans). This approval authorizes the sale of SmoothX for use in radiology procedures in Canada. SmoothX is specifically designed for use on CT Scans of the abdomen and gastrointestinal tract in both adults and pediatric patients.
Voyageur has four additional barium radiographic contrast Products that are currently under review by Health Canada and we expect product licences to be forthcoming.
“Voyageur’s business plan has always been to launch Barium Contrast Radiographic Suspension products into the Canadian marketplace initially, then pursue other markets. This approval is the critical milestone to allow our company to transition to a cash flowing pharmaceutical company” reports Brent Willis, Voyageur’s CEO.
- Category: Biotech
- Published: 12 February 2021
- Written by Editor